Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair

Zurück zum Zitat Li S, Lu H, Wang Z, Hu Q, Wang H, Xiang R, Chiba T, Wu X (2019) ERCC1/XPF is important for repair of dna double-strand breaks containing secondary structures. iScience 16:63–78. https://doi.org/10.1016/j.isci.2019.05.017CrossRefPubMedPubMedCentral Li S, Lu H, Wang Z, Hu Q, Wang H, Xiang R, Chiba T, Wu X (2019) ERCC1/XPF is important for repair of dna double-strand breaks containing secondary structures. iScience 16:63–78. https://​doi.​org/​10.​1016/​j.​isci.​2019.​05.​017CrossRefPubMedPubMedCentral

Zurück zum Zitat Zhang H, Chen Z, Ye Y, Ye Z, Cao D, Xiong Y, Srivastava M, Feng X, Tang M, Wang C, Tainer JA, Chen J (2019) SLX4IP acts with SLX4 and XPF–ERCC1 to promote interstrand crosslink repair. Nucleic Acids Res 47:10181–10201. https://doi.org/10.1093/nar/gkz769CrossRefPubMedPubMedCentral Zhang H, Chen Z, Ye Y, Ye Z, Cao D, Xiong Y, Srivastava M, Feng X, Tang M, Wang C, Tainer JA, Chen J (2019) SLX4IP acts with SLX4 and XPF–ERCC1 to promote interstrand crosslink repair. Nucleic Acids Res 47:10181–10201. https://​doi.​org/​10.​1093/​nar/​gkz769CrossRefPubMedPubMedCentral

Zurück zum Zitat Faridounnia M, Folkers GE, Boelens R (2018) Function and interactions of ERCC1–XPF in DNA damage response. Molecules 23:3205. https://doi.org/10.3390/molecules23123205CrossRefPubMedCentral Faridounnia M, Folkers GE, Boelens R (2018) Function and interactions of ERCC1–XPF in DNA damage response. Molecules 23:3205. https://​doi.​org/​10.​3390/​molecules2312320​5CrossRefPubMedCentral

Zurück zum Zitat Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM (2018) Targeting the DNA repair endonuclease ERCC1–XPF with green tea polyphenol epigallocatechin-3-gallate (EGCG) and its prodrug to enhance cisplatin efficacy in human cancer cells. Nutrients 10:1644. https://doi.org/10.3390/nu10111644CrossRefPubMedCentral Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM (2018) Targeting the DNA repair endonuclease ERCC1–XPF with green tea polyphenol epigallocatechin-3-gallate (EGCG) and its prodrug to enhance cisplatin efficacy in human cancer cells. Nutrients 10:1644. https://​doi.​org/​10.​3390/​nu10111644CrossRefPubMedCentral

Zurück zum Zitat McNeil EM, Melton DW (2012) DNA repair endonuclease ERCC1–XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res 40:9990–10004. https://doi.org/10.1093/nar/gks818CrossRefPubMedPubMedCentral McNeil EM, Melton DW (2012) DNA repair endonuclease ERCC1–XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res 40:9990–10004. https://​doi.​org/​10.​1093/​nar/​gks818CrossRefPubMedPubMedCentral

Zurück zum Zitat Cummings M, Higginbottom K, McGurk CJ, Wong OGW, Köberle B, Oliver RTD, Masters JR (2006) XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 72:166–175. https://doi.org/10.1016/j.bcp.2006.04.025CrossRefPubMed Cummings M, Higginbottom K, McGurk CJ, Wong OGW, Köberle B, Oliver RTD, Masters JR (2006) XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 72:166–175. https://​doi.​org/​10.​1016/​j.​bcp.​2006.​04.​025CrossRefPubMed

Zurück zum Zitat Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ (2005) Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 327:225–233. https://doi.org/10.1016/j.bbrc.2004.12.008CrossRefPubMed Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ (2005) Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 327:225–233. https://​doi.​org/​10.​1016/​j.​bbrc.​2004.​12.​008CrossRefPubMed

Zurück zum Zitat Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM (2010) Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst) 9:745–753. https://doi.org/10.1016/j.dnarep.2010.03.010CrossRef Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM (2010) Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst) 9:745–753. https://​doi.​org/​10.​1016/​j.​dnarep.​2010.​03.​010CrossRef

Zurück zum Zitat Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El SR, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C (2013) Small molecule inhibitors of ERCC1–XPF protein–protein interaction synergize alkylating agents in cancer cellss. Mol Pharmacol 84:12–24. https://doi.org/10.1124/mol.112.082347CrossRefPubMed Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El SR, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C (2013) Small molecule inhibitors of ERCC1–XPF protein–protein interaction synergize alkylating agents in cancer cellss. Mol Pharmacol 84:12–24. https://​doi.​org/​10.​1124/​mol.​112.​082347CrossRefPubMed

Zurück zum Zitat Gentile F, Elmenoufy AH, Ciniero G, Jay D, Karimi-Busheri F, Barakat KH, Weinfeld M, West FG, Tuszynski JA (2020) Computer-aided drug design of small molecule inhibitors of the ERCC1–XPF protein–protein interaction. Chem Biol Drug Des 95:460–471. https://doi.org/10.1111/cbdd.13660CrossRefPubMed Gentile F, Elmenoufy AH, Ciniero G, Jay D, Karimi-Busheri F, Barakat KH, Weinfeld M, West FG, Tuszynski JA (2020) Computer-aided drug design of small molecule inhibitors of the ERCC1–XPF protein–protein interaction. Chem Biol Drug Des 95:460–471. https://​doi.​org/​10.​1111/​cbdd.​13660CrossRefPubMed

Zurück zum Zitat Dietlein F, Thelen L, Reinhardt HC (2014) Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet 30:326–339. https://doi.org/10.1016/j.tig.2014.06.003CrossRefPubMed Dietlein F, Thelen L, Reinhardt HC (2014) Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet 30:326–339. https://​doi.​org/​10.​1016/​j.​tig.​2014.​06.​003CrossRefPubMed

Zurück zum Zitat Hill JM, Speer RJ (1982) Organo-platinum complexes as antitumor agents. (Review). Anticancer Res 2:173–185PubMed Hill JM, Speer RJ (1982) Organo-platinum complexes as antitumor agents. (Review). Anticancer Res 2:173–185PubMed

Zurück zum Zitat Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FKM, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D’Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Deberardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25:486–541. https://doi.org/10.1038/s41418-017-0012-4CrossRefPubMedPubMedCentral Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FKM, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D’Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Deberardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25:486–541. https://​doi.​org/​10.​1038/​s41418-017-0012-4CrossRefPubMedPubMedCentral

Zurück zum Zitat Nirmala JG, Lopus M (2019) Cell death mechanisms in eukaryotes. Cell Biol Toxicol 36:145–164. https://doi.org/10.1007/s10565-019-09496-2CrossRefPubMed Nirmala JG, Lopus M (2019) Cell death mechanisms in eukaryotes. Cell Biol Toxicol 36:145–164. https://​doi.​org/​10.​1007/​s10565-019-09496-2CrossRefPubMed

Zurück zum Zitat Elmenoufy AH, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, Weilbeer C, Mani RS, Barakat KH, Tuszynski JA, Weinfeld M, West FG (2019) Targeting DNA repair in tumor cells via inhibition of ERCC1–XPF. J Med Chem 62:7684–7696. https://doi.org/10.1021/acs.jmedchem.9b00326CrossRefPubMed Elmenoufy AH, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, Weilbeer C, Mani RS, Barakat KH, Tuszynski JA, Weinfeld M, West FG (2019) Targeting DNA repair in tumor cells via inhibition of ERCC1–XPF. J Med Chem 62:7684–7696. https://​doi.​org/​10.​1021/​acs.​jmedchem.​9b00326CrossRefPubMed

Zurück zum Zitat Elmenoufy AH, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, Mani RS, Ciniero G, Tuszynski JA, Weinfeld M, West FG (2020) Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1–XPF inhibitors targeting DNA repair pathway. Eur J Med Chem 204:112658. https://doi.org/10.1016/j.ejmech.2020.112658CrossRefPubMed Elmenoufy AH, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, Mani RS, Ciniero G, Tuszynski JA, Weinfeld M, West FG (2020) Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1–XPF inhibitors targeting DNA repair pathway. Eur J Med Chem 204:112658. https://​doi.​org/​10.​1016/​j.​ejmech.​2020.​112658CrossRefPubMed

Zurück zum Zitat Labute P (2008) The generalized born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29:1693–1698. https://doi.org/10.1002/jcc.20933CrossRefPubMed Labute P (2008) The generalized born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29:1693–1698. https://​doi.​org/​10.​1002/​jcc.​20933CrossRefPubMed

Zurück zum Zitat Volpe A, Racioppi M, D’Agostino D, Cappa E, Filianoti A, Bassi PF (2010) Mitomycin C for the treatment of bladder cancer. Minerva Urol Nefrol 62:133–144PubMed Volpe A, Racioppi M, D’Agostino D, Cappa E, Filianoti A, Bassi PF (2010) Mitomycin C for the treatment of bladder cancer. Minerva Urol Nefrol 62:133–144PubMed

Zurück zum Zitat Florea A-M, Büsselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3:1351–1371. https://doi.org/10.3390/cancers3011351CrossRef Florea A-M, Büsselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3:1351–1371. https://​doi.​org/​10.​3390/​cancers3011351CrossRef

Zurück zum Zitat Oun R, Moussa YE, Wheate NJ (2018) The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalt Trans 47:6645–6653. https://doi.org/10.1039/c8dt00838hCrossRef Oun R, Moussa YE, Wheate NJ (2018) The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalt Trans 47:6645–6653. https://​doi.​org/​10.​1039/​c8dt00838hCrossRef

Zurück zum Zitat Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM (2016) Identification of small molecule inhibitors of ERCC1–XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget 7:75104–75117. https://doi.org/10.18632/oncotarget.12072CrossRefPubMedPubMedCentral Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM (2016) Identification of small molecule inhibitors of ERCC1–XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget 7:75104–75117. https://​doi.​org/​10.​18632/​oncotarget.​12072CrossRefPubMedPubMedCentral

Zurück zum Zitat McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, Jones HM, Khurana P, Wallace C, Chapman T, Wear MA, Walkinshaw MD, Saxty B, Melton DW (2015) Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair (Amst) 31:19–28. https://doi.org/10.1016/j.dnarep.2015.04.002CrossRef McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, Jones HM, Khurana P, Wallace C, Chapman T, Wear MA, Walkinshaw MD, Saxty B, Melton DW (2015) Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair (Amst) 31:19–28. https://​doi.​org/​10.​1016/​j.​dnarep.​2015.​04.​002CrossRef

Zurück zum Zitat Thomas AM, Brolih S, McGouran JF, El-Sagheer AH, Ptchelkine D, Jones M, McDonald NQ, McHugh PJ, Brown T (2019) Optimised oligonucleotide substrates to assay XPF-ERCC1 nuclease activity for the discovery of DNA repair inhibitors. Chem Commun 55:11671–11674. https://doi.org/10.1039/c9cc05476fCrossRef Thomas AM, Brolih S, McGouran JF, El-Sagheer AH, Ptchelkine D, Jones M, McDonald NQ, McHugh PJ, Brown T (2019) Optimised oligonucleotide substrates to assay XPF-ERCC1 nuclease activity for the discovery of DNA repair inhibitors. Chem Commun 55:11671–11674. https://​doi.​org/​10.​1039/​c9cc05476fCrossRef

Zurück zum Zitat Chapman TM, Gillen KJ, Wallace C, Lee MT, Bakrania P, Khurana P, Coombs PJ, Stennett L, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B (2015) Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1–XPF. Bioorgan Med Chem Lett 25:4097–4103. https://doi.org/10.1016/j.bmcl.2015.08.031CrossRef Chapman TM, Gillen KJ, Wallace C, Lee MT, Bakrania P, Khurana P, Coombs PJ, Stennett L, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B (2015) Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1–XPF. Bioorgan Med Chem Lett 25:4097–4103. https://​doi.​org/​10.​1016/​j.​bmcl.​2015.​08.​031CrossRef

Zurück zum Zitat Basu AK, Hanrahan CJ, Malia SA, Kumar S, Bizanek R, Tomasz M (1993) Effect of site-specifically located mitomycin C-DNA monoadducts on in vitro DNA synthesis by DNA Polymerases. Biochemistry 32:4708–4718. https://doi.org/10.1021/bi00069a004CrossRefPubMed Basu AK, Hanrahan CJ, Malia SA, Kumar S, Bizanek R, Tomasz M (1993) Effect of site-specifically located mitomycin C-DNA monoadducts on in vitro DNA synthesis by DNA Polymerases. Biochemistry 32:4708–4718. https://​doi.​org/​10.​1021/​bi00069a004CrossRefPubMed